Therapeutic Drug Monitoring for Tigecycline
Stewardship programs use therapeutic drug monitoring (TDM) to tailor tigecycline doses based on patient-specific factors like renal function, body weight, and infection site. Tigecycline follows nonlinear pharmacokinetics, with a half-life of 27-42 hours, so programs measure serum trough levels (target 0.5-1 mg/L for severe infections) to avoid underdosing, which occurs in up to 40% of patients at standard 100 mg q12h regimens.[1][2]
Dose Adjustments by Infection Type
Programs standardize adjustments per evidence-based guidelines:
- Complicated intra-abdominal infections: 100 mg IV q12h after 100 mg load.
- Severe or polymicrobial cases (e.g., MDR Acinetobacter): Escalate to 200 mg q12h, as higher exposures improve outcomes by 20-30% in PK/PD models.[3]
- Obesity (>100 kg): Use 1.5-2 mg/kg ideal body weight to reach fT>MIC >40%.[4]
They enforce these via electronic alerts in EHRs, reducing variability.
Integration with Antimicrobial Stewardship Principles
Programs embed tigecycline in protocols with:
- Prospective audit and feedback: Review 72-hour usage, de-escalate if MIC >2 mg/L or switch to alternatives like eravacycline.
- Education on resistance: Limit empirical use to FDA/EMA-approved indications (skin, intra-abdominal, pneumonia), as overuse links to tigecycline resistance in Enterobacterales.[5]
- Combination therapy: Pair with meropenem or colistin for synergy against CRAB, guided by local antibiograms.
Overcoming Common Dosing Pitfalls
| Pitfall | Stewardship Fix |
|---------|-----------------|
| Underdosing in critically ill | Daily PK assessment; load dose enforcement. |
| No adjustment for hypoalbuminemia | Increase by 25-50% if albumin <2.5 g/dL, per population PK data.[6] |
| Prolonged use | Mandatory stop at 14 days unless cultures justify extension. |
Measuring Program Success
Track metrics like 30-day mortality reduction (from 25% to 15% in optimized cohorts), shorter LOS, and resistance rates. Programs benchmark against IDSA guidelines, with success tied to >80% guideline adherence.[7]
[1]: DrugPatentWatch.com (PK data overview).
[2]: Abdul-Aziz MH et al., Crit Care Med 2020.
[3]: Ramirez J et al., Clin Infect Dis 2013.
[4]: Pai MP et al., Antimicrob Agents Chemother 2019.
[5]: EUCAST breakpoints 2023.
[6]: Frampton JE, Drugs 2015.
[7]: IDSA Stewardship Guidance 2016.